Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol HOWL
- Company Werewolf Therapeutics, Inc.
- Price $2.85
- Changes Percentage 39.02
- Change 0.8
- Day Low $2.55
- Day High $3.28
- Year High $8.19
- Year Low $1.57
- Market Cap $124,551,270
- Price Avg 50 EMA (D) $2.1
- Price Avg 200 EMA (D) $4.11
- Exchange NASDAQ
- Volume 9,858,529
- Average Volume 160,492
- Open $2.7
- Previous Close $2.05
- EPS -1.38
- PE -2.07
- Earnings Announcement 2024-11-07 12:00:00
- Shares Outstanding $43,702,200
Company brief: WEREWOLF THERAPEUTICS, INC. (HOWL )
- Healthcare
- Biotechnology
- Dr. Daniel J. Hicklin Ph.D.
- https://werewolftx.com
- US
- N/A
- 04-30-2021
- US95075A1079
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
HOWL Corporation News
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting
globenewswire.com -- WATERTOWN, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development...